Holen Sie sich die Stockscreener-App
13.77
4.79%
0.63
Schlusskurs vom Vortag:
$13.14
Offen:
$13.03
24-Stunden-Volumen:
550.85K
Relative Volume:
0.71
Marktkapitalisierung:
$638.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-161.15M
KGV:
-3.7067
EPS:
-3.7149
Netto-Cashflow:
$-138.61M
1W Leistung:
+9.29%
1M Leistung:
+6.41%
6M Leistung:
-23.61%
1J Leistung:
+0.00%
1-Tages-Spanne:
$13.00
$14.14
1-Wochen-Bereich:
$12.12
$14.14
52-Wochen-Spanne:
$9.10
$40.43
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Firmenname
Maplight Therapeutics Inc
Sektor
Branche
Telefon
650-839-4360
Adresse
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
13.77 | 520.82M | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Needham | Buy |
| 2026-04-07 | Eingeleitet | TD Cowen | Buy |
| 2026-03-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-11-21 | Eingeleitet | Jefferies | Buy |
| 2025-11-21 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-21 | Eingeleitet | Stifel | Buy |
Alle ansehen
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study - Business Wire
Blue Owl Capital Holdings LP Takes $26.16 Million Position in Maplight Therapeutics, Inc. $MPLT - MarketBeat
MPLT: MapLight Therapeutics, Inc.Financial Overview - Zacks Investment Research
MapLight Therapeutics (MPLT): Nan Fung group holds passive stake above 5% - Stock Titan
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7%Should You Sell? - MarketBeat
MapLight Therapeutics (MPLT) grants CDO 24K options and 6K RSUs - Stock Titan
MapLight (NASDAQ: MPLT) grants CEO 93,955 options and 23,145 RSUs - Stock Titan
MapLight (MPLT) Reported Results Review: The EPS Result Is Below Expectation in the Reported Period; Trading-Day Reaction: Shares Rise 5.11% in Latest TradingGuidance Downgrade Alert - Vinanet
Catalyst4 builds 49.9% MapLight (MPLT) stake in private share deal - Stock Titan
MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Therapeutics announces $150M private placement - TipRanks
Maplight Therapeutics (NASDAQ:MPLT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
LifeSci Capital Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $37 - Moomoo
BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20 - moomoo.com
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta - Endpoints News
MapLight Therapeutics Announces $150 Million Private Placement Financing - marketscreener.com
MapLight bags USD 150m after muscarinic schizophrenia Phase II win - AllSci
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Cut to $28.77, Implies 148% Upside - TradingView
Dividend HistoryMapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight Reports Positive Phase 2 Schizophrenia Data, Plans Phase 3 Trial - Minichart
MapLight Q2 Results: Net loss widens to $60.2M, cash runway extends to 2028 - scanx.trade
MapLight Therapeutics Secures $150 Million Through Private Stock Placement - Kalkine Media
MapLight Therapeutics Announces Q2 2026 Financial Results with Rising Losses and R&D Expenses - Kalkine Media
Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MapLight Therapeutics (Nasdaq: MPLT) boosts cash with $150M private deal - Stock Titan
MapLight Therapeutics 2Q 2026: Net loss $60.2M, EPS $(1.32) — 10-Q Summary - TradingView
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Maplight Therapeutics (NASDAQ:MPLT) Trading Up 6.4%Here's Why - MarketBeat
Latham Advises on MapLight Therapeutics’ US$150 Million Private Placement Financing - Latham & Watkins LLP
MapLight Therapeutics secures $150 million financing - The Pharma Letter
MapLight Therapeutics stock jumps on $150M private placement By Investing.com - Investing.com Nigeria
Why is MapLight Therapeutics stock rallying today? - Investing.com
MapLight Therapeutics raises $150 million in private placement - Investing.com
Why is MapLight Therapeutics stock rallying today? By Investing.com - Investing.com South Africa
Zealand’s royalty deal; Khartis raises money for TED drug - Endpoints News
MapLight Therapeutics stock jumps on $150M private placement - Investing.com
MapLight Therapeutics Launching $150 Million Private Placement Financing - marketscreener.com
MapLight Therapeutics raises $150 million in private placement By Investing.com - Investing.com Australia
Maplight Therapeutics (MPLT) Earnings Date and Reports 2026 - MarketBeat
UBS Downgrades MapLight Therapeutics(MPLT.US) to Hold Rating, Cuts Target Price to $13 - moomoo.com
MPLT Downgraded by UBS -- Price Target Lowered to $13.00 - GuruFocus
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownTime to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating MapLight Therapeutics, Inc. (MPLT) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating MapLight Ther - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MapLight Therapeutics, Inc. (MPLT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 6.4%Time to Sell? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating MapLight Therapeutics, Inc. (MPLT) And Encourages Investors to Connect - ACCESS Newswire
MapLight Therapeutics, Inc. (MPLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
MapLight Therapeutics (MPLT) Gains 2.79% as Shares Push Toward Key ResistanceBPI Bull Correction - vinanet.vn
Bronstein, Gewirtz & Grossman, LLC Encourages MapLight Therapeutics, Inc. (MPLT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Maplight Therapeutics (NASDAQ:MPLT) Insider Sells 22,082 Shares of Stock - MarketBeat
Finanzdaten der Maplight Therapeutics Inc-Aktie (MPLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maplight Therapeutics Inc-Aktie (MPLT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lillie James Woodruff | Chief Scientific Officer |
Aug 03 '26 |
Sale |
12.54 |
22,082 |
276,908 |
202,380 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):